STOCK TITAN
  1. Home
  2. News
  3. MIRM

Mirum Pharmaceuticals Inc - MIRM STOCK NEWS

Welcome to our dedicated news page for Mirum Pharmaceuticals (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mirum Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mirum Pharmaceuticals's position in the market.

News
Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has appointed Dr. Joanne Quan as Chief Medical Officer to lead the global clinical development, clinical operations, and safety programs for their pipeline of programs addressing rare diseases. In addition, Peter Radovich has been promoted to President and Chief Operating Officer, overseeing commercial, corporate development, and supply chain functions. Dr. Quan brings nearly three decades of experience in the development of medications for rare conditions, and her appointment strengthens the team and leadership in rare disease at Mirum.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
management
-
News
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) granted inducement awards to seven new employees, consisting of non-qualified stock options to purchase 50,950 shares of common stock and 25,480 restricted stock units under Mirum’s 2020 Inducement Plan. Each stock option has an exercise price per share equal to $26.26 per share and will vest over four years, while the RSUs will vest over three years. The awards are subject to the terms and conditions of Mirum’s 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
none
-
News
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) expects $186-188 million in total revenue and $178-180 million net product sales for 2023, with LIVMARLI net product sales of $141-143 million, representing approximately 89% year-over-year growth. The company also provided corporate updates and a full-year 2024 outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
none
News
Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (MIRM) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
conferences
-
News
Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced the Phase 2 EMBARK study results for LIVMARLI® (maralixibat) oral solution as adjuvant therapy to Kasai surgery in patients with biliary atresia. The study did not meet primary or secondary endpoints, including mean change in bilirubin from baseline to Week 26. LIVMARLI was well-tolerated, with no new safety findings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.87%
Tags
clinical trial
-
News
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (MIRM) granted inducement awards, including non-qualified stock options and restricted stock units, to five new employees under its 2020 Inducement Plan. The stock options have an exercise price of $32.86 per share and will vest over four years, while the RSUs will vest over three years. The awards are subject to the terms and conditions of the Inducement Plan and the applicable award agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) to present at the 6th annual Evercore ISI HealthCONx Conference on November 28th, 2023. The company focuses on acquiring, developing, and commercializing therapies for rare and orphan diseases. Visit the corporate website for webcast links and more details.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
conferences
-
News
Mirum Pharmaceuticals Presents New Data at The Liver Meeting®
Rhea-AI Summary
MIRM: Mirum Pharmaceuticals Presents Positive Data on LIVMARLI and Volixibat Programs at The Liver Meeting. The data features long-term efficacy and safety of LIVMARLI in patients with progressive familial intrahepatic cholestasis (PFIC) and the impact of volixibat on patients with intrahepatic cholestasis of pregnancy (ICP).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.57%
Tags
none
-
News
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) Inducement Awards to New Employees: Mirum Pharmaceuticals, Inc. announced the granting of inducement awards, including non-qualified stock options and restricted stock units, to five new employees under the 2020 Inducement Plan. Each stock option has an exercise price per share equal to $28.61 and will vest over four years, while the RSUs will vest over three years. The awards are subject to the terms and conditions of the Inducement Plan and an applicable award agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. is set to participate in a fireside chat at the 2023 UBS Biopharma Conference on November 8th. The company focuses on developing and commercializing therapies for rare and orphan diseases. Investors can access webcast links and more information on Mirum's corporate website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.67%
Tags
conferences
Stock MIRM logo
Mirum Pharmaceuticals Inc

Nasdaq:MIRM

MIRM Rankings

#2327 Ranked by Market Cap
#907 Ranked by Stock Gains
N/A Ranked by Dividends

MIRM Stock Data

1.16B
35.19M
2.25%
112.23%
17.36%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Foster City

About MIRM

mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.